🇺🇸

US SEC Filing Intelligence

· daily

General Federal Contracts — March 05, 2026

Eight bullish federal contracts totaling $1.88B highlight robust U.S. government demand for space/defense, healthcare administration, and infrastructure construction, with multi-year performance periods extending to 2029 providing revenue stability for key contractors. BAE Systems (Ball Corp parent) captures 2 contracts worth $645M, underscoring defense/space exposure, while construction awards exceed $540M across 3 deals. Unexercised options exceed $400M, signaling near-term upside amid firm-fixed-price and cost-plus structures.

8 total filings
· daily

All NASA Contracts — March 05, 2026

A single $476M NASA contract awarded to BAE Systems Space & Mission Systems Inc. (Ball Corp subsidiary) underscores stable long-term revenue in space vehicle components through 2029, with $141M already outlayed and $336M remaining. This non-competitive, cost-plus-award-fee deal signals bullish commitment to OMPS program engineering but carries execution risks from its 19-year duration and $23M subawards. Investors should prioritize monitoring outlays and performance fees for revenue visibility.

1 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 05, 2026

Across 50 filings from the S&P 500 Consumer Staples stream and adjacent sectors, sentiment is predominantly mixed (18/50 filings), reflecting resilient top-line growth in staples/wholesale leaders like Costco (+9.1% YoY Q2 sales, +7.4% comps) and BJ's (+4.6% FY sales, +9.5% membership fees) offset by softness elsewhere (Kroger FY sales flat YoY, Clarus FY sales -5.3% YoY). Period-over-period trends show average revenue growth of ~+5% YoY in reporting consumer firms (e.g., 6/12 with sales data >+4% YoY) but margin compression in 7/12 (avg -100 bps, e.g., Clarus gross margin -190 bps, Kroger OG&A +29 bps FY), impairments rampant (10+ filings, e.g., Kroger $2.5B, Lineage $14.8M), and narrowing losses in turnarounds (flyExclusive net loss -34% YoY). Capital allocation tilts shareholder-friendly with buybacks (Kroger $7.5B completed +$2B approved, BJ's $117.7M Q4) and dividend hikes (Philip Morris to $1.47, Korn Ferry +14.6% to $0.55), while financing ramps for liquidity (Pulmonx $60M facility, Vivakor $750k note amid distress). Forward-looking signals mixed: upbeat guidance (Clarus 2026 sales +2-6% YoY, EBITDA to $9-11M), but narrows (Methode FY26 sales $950M-1B). Portfolio-level: staples show defensive comp sales (+1-7% YoY avg), but broader distress in non-core (Monroe Capital NII -53% YoY). Critical implications: favor wholesale staples for stability, monitor impairments/debt for staples-adjacent risks.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 05, 2026

Across 92 SEC filings from the USA S&P 500 Industrials intelligence stream (including energy services, transportation, machinery, and adjacent sectors like aerospace/defense), mixed sentiment prevails in 70% of cases, reflecting revenue growth in production-heavy firms (avg +15% YoY in energy/oil like Granite Ridge +27%, SandRidge +12%) offset by service declines (Ranger Energy -4% FY revenue) and margin compression (avg -50 bps where reported). Period-over-period trends show improving net losses in 40% of biotechs/pharmas (e.g., Gevo -57%, Lexicon -75%) but widening in others (EyePoint +77%), with capital allocation favoring dividends/buybacks (Kroger $7.5B repurchases, Ranger $42.9M FCF to returns >40%). M&A/SPAC activity surges (Pasqal $2B Bleichroeder merger H2 2026, Home Bancshares MCBI Q2 2026), alongside leadership churn in transportation (Delta exec promotions). Forward-looking guidance clusters around modest 2026 growth (Granite Ridge +9%, Traeger flat revenues), building a catalyst calendar heavy in Q2 trial data/FDA meetings. Portfolio-level, Industrials exhibit resilient production amid pricing pressures, signaling selective upside in energy services/transport but risks from impairments/debt.

55 high priority 37 medium 92 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 05, 2026

The sole filing in the USA S&P 500 Energy intelligence stream is an 8-K from Copper Property CTL Pass Through Trust, announcing a monthly cash distribution of $0.082844 per trust certificate, payable on March 10, 2026, to holders of record on March 9, 2026. This reflects positive sentiment (rated positive) and steady capital allocation focused on shareholder returns via distributions, with materiality at 6/10. No period-over-period comparisons, YoY/QoQ trends, insider trading activity, forward-looking guidance, M&A details, financial ratios, or operational metrics were disclosed in the filing, limiting quantitative trend analysis across the sector. The availability of the monthly report for the period ending February 28, 2026, on the investor website (www.ctltrust.net) enhances transparency. Key implication: This signals reliable income generation in the energy sector trust space, potentially appealing to yield-seeking investors amid stable cash flows, though absence of comparative data prevents identifying growth or margin trends at a portfolio level.

1 medium 1 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 05, 2026

Across the 416 pre-analyzed SEC filings from S&P 500 Financials and adjacent sectors (though data skews to energy, biotech, retail, and industrials), overarching themes include mixed FY2025 results with revenue growth in 62% of reporting companies (avg +12% YoY) offset by margin compression in 58% (avg -85 bps YoY), driven by higher operating costs and impairments; capital allocation favors buybacks/dividends in 28 companies (e.g., $7.5B Kroger repurchase completed, $2B authorized). Insider activity shows neutral conviction with appointments dominant (e.g., 15 new directors/CFOs) but few buys/sells. Forward-looking guidance is cautious with 45% raising revenue targets (avg +10%) but 32% trimming EBITDA/margins amid economic pressures. M&A accelerates (12 deals, avg $500M+ valuation, e.g., USA Rare Earth $73M acquisition), signaling consolidation. Portfolio-level trends: EBITDA flat/declining in 55% despite revenue beats, highlighting cost inflation; energy/biotech outliers with 20-50% YoY declines in key metrics. Implications: Favor resilient dividend payers and M&A targets; avoid margin squeezes in retail/energy.

227 high priority 189 medium 416 total filings
· daily

US Material Events SEC 8-K Filings — March 05, 2026

Across 84 SEC filings from March 5, 2026, dominant themes include widespread executive churn (25+ filings on appointments/departures, especially CFO/CAO roles like Sysco/McKesson swaps, Trulieve termination), robust M&A/divestiture activity (e.g., rare earth consolidation via USA Rare Earth/TMRC $73M deal, Six Flags $331M park sale), and financing enhancements (20+ credit amendments/extensions like RPM to 2031, Simon $5B rev revolver). Period-over-period trends show mixed revenue performance: growth in OptimizeRx FY2025 +19% YoY to $109.4M, Full House FY2025 +3.5% to $302.4M, Camp4 cash +71% to $109.5M, but declines in GoPro FY2025 -19% to $652M and hardware -21.5%; margins compressed in GoPro -290bps Q4 to 31.8%, flat EBITDA in Full House. Capital allocation leans shareholder-friendly with EPAM $300M ASR (remaining $452.5M program), OptimizeRx $10M buyback, AZZ board refresh for M&A/ESG. Critical implications: Positive for rare earths/tech consolidation amid supply chain risks, caution on media distress (Cumulus Ch11) and cannabis/consumer volatility; portfolio-level alpha in financing-secured growth names vs. restructuring risks.

84 high priority 84 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 05, 2026

Across 20 SEC filings from diverse sectors mislabeled under S&P 500 Technology stream, dominant themes include robust revenue growth in 9/20 companies (avg +35% YoY where quantified, e.g., Evommune +86%, Entravision +23%, CrowdStrike +22%) offset by widening net losses in 10/20 (e.g., CrowdStrike loss to $162.5M, Entravision to $79.2M) due to surging OpEx (avg +25% YoY). Mixed sentiment prevails (12/20 filings), with positive catalysts like biotech trials (Altimmune Q3 2026 RECLAIM data, Evommune 2Q/2H26 Phase 2b), capital allocation via dividends (Iridium $0.15/share, Entravision $0.20), M&A/divestitures (CYH $112M hospital sale Q2 2026 close, Genco vessel acquisition), and restructurings (Cumulus prepackaged Ch.11). Margin compressions hit 7/15 with data (avg -100bps, e.g., NCS services to 45%, Weave onboarding -153%), while cash positions strengthened in biotechs (Altimmune +107% YoY to $274M, Evommune to $216.7M). Insider activity limited to appointments (Acadia new director, Altimmune CEO change), no major buys/sells. Portfolio implications: Bullish on turnaround growth (Adial loss -40% YoY), bearish on bankruptcy risks (Cumulus); monitor Q2 2026 catalysts for alpha in undervalued assets.

14 high priority 6 medium 20 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 05, 2026

Across 22 NASDAQ-100 filings, mixed sentiment prevails with 12/15 annual reports showing average revenue growth of 25% YoY (range +9% Costco to +86% Evommune) driven by tech/services/advertising segments, but offset by profitability pressures including widened losses (e.g., +3% Evommune, +12% Metagenomi), impairments (Entravision $55M), and margin declines (NCS services 45% vs 49%). Biotech cluster (Altimmune, Evommune, Metagenomi, Adial) highlights pipeline catalysts and cash runways to 2027-28 despite revenue volatility (-52% Metagenomi). Media/comms face headwinds (Cumulus bankruptcy prep, Entravision media -20-32% YoY), while retail (Costco +9% sales) and shipping (Genco acquisition) shine. Capital allocation steady with dividends (Iridium $0.15, Entravision $0.20 unchanged), reverse split (Aditxt 1:8), and M&A (CYH $112M sale Q2 2026). Portfolio implications: Favor consumer/biotech catalysts, avoid distressed media, monitor restructuring votes/debt closes for near-term volatility.

15 high priority 7 medium 22 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 05, 2026

Across 118 SEC filings from the USA Dow Jones 30 intelligence stream (covering diverse sectors but focused on blue-chips and related), overarching themes include resilient YoY revenue growth averaging +15% in 35/118 companies (e.g., Grid Dynamics +17.5%, CrowdStrike +22%, Hippo +26%) offset by widespread margin compression (-100 to -200 bps in 28 firms like OLAPLEX -27.6% Adj EBITDA drop) and mixed sentiment (62% mixed, 18% positive). Period-over-period trends show QoQ improvements in Q4 for 22 companies (e.g., Ranger Energy revenue +10% QoQ) but FY losses widening in tech/services (CrowdStrike net loss -$162.5M vs -$15.2M prior). Capital allocation remains shareholder-friendly with buybacks/dividends in 15 filings (e.g., BJ's $117.7M Q4 repurchases, Ranger 994k shares), while forward guidance signals caution (e.g., OLAPLEX FY26 sales flat, Grove revenue decline). M&A/divestitures active (Six Flags $331M parks sale, Aptiv spin-off), and insider conviction mixed with no major sales but leadership changes (Trulieve CAO termination). Portfolio implications: Favor margin-resilient growers like Invivyd (revenue doubled) over compressors; monitor energy transition plays (Greenidge AI/HPC shift). Critical developments: AI-driven growth (Grid Dynamics AI 25% of Q4) vs expense surges, positioning selective longs in tech/finance amid macro softness.

70 high priority 48 medium 118 total filings
· daily

US SEC Filings Daily Market Digest — March 05, 2026

Across 481 SEC filings for March 5, 2026, US markets show mixed corporate health with retail leaders like Burlington Stores (+9% FY sales, +2% comps) and BJ's (+4.6% FY sales) outperforming amid modest guidance (Burlington FY26 +8-10%), while consumer names like GoPro (-19% revenue) and Grove Collaborative (-15%) struggle with margin erosion. Biotech and pharma exhibit robust revenue surges (REGENXBIO +105% YoY, Lexicon +60%, Cryoport +12.4%) but persistent net losses and cash burn, offset by positive pipeline catalysts (e.g., Tenaya-Alnylam collab up to $1.13B milestones). Energy firms report production gains (Granite Ridge +27% YoY Q4, SandRidge +12% FY) and reserve growth (+9.5-15%), though revenues vary with prices; SPAC activity surges with Pasqal's $2B merger and multiple quantum deals. Portfolio trends reveal margin compression in 8/15 tech filings (avg -120bps despite +15-30% revenue), retail comp sales +1-5% avg in outperformers vs declines elsewhere, and capital returns via buybacks/dividends in 12 firms (e.g., EPAM $300M ASR, Kroger $7.5B repurchase). Insider patterns absent but management conviction via repurchases in Ranger (994k shares), Burlington ($117M Q4). Forward catalysts cluster in Q2 2026 (Northern Data acquisition, Pasqal Nasdaq listing, multiple earnings). Overall, actionable alpha in energy production plays and retail leaders amid quiet M&A uptick.

253 high priority 228 medium 481 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 05, 2026

Across 71 SEC filings from diverse sectors mislabeled under S&P 500 Consumer Discretionary (including energy, financials, tech, and true disc like entertainment), overarching themes include robust revenue/production growth averaging 20-50% YoY in 25+ companies (e.g., Granite Ridge +27% prod, FTC Solar +149% Q4 rev, Profound Medical +50%), tempered by persistent net losses or margin compression in 30+ firms due to higher opex/LOE (e.g., flyExclusive retail -39% Q4, Mobile Infra rev -5%). Capital allocation shines with aggressive buybacks (Zillow +$1.25B to $1.3B capacity, Paycom +$200M) and dividend hikes (Korn Ferry +14.6% to $0.55), signaling management conviction amid mixed sentiment (45/71 mixed/neutral). Forward-looking data reveals optimistic 2026 guidances in energy/tech (SandRidge 6.4-7.7 MMBoe, Bridger $135-145M rev, TriSalus $60-62M), spin-offs (Aptiv Versigent April 1), and divestitures (Six Flags $331M parks sale). Portfolio-level trends show outperformance in production/reserves growth (energy avg +15-28% YoY) vs deteriorating retail/consumer metrics (flyExclusive fractional retail -8% YTD, NIKE $300M restructuring charges). Critical implications: prioritize capital return plays and guided growth; avoid prolonged loss-makers like Research Frontiers (cash -67%).

32 high priority 39 medium 71 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 05, 2026

Across 31 SEC filings from the USA S&P 500 Healthcare stream (with broader S&P exposure), overarching themes include robust revenue growth in healthcare/biotech (e.g., TriSalus 53% YoY to $45.2M, Caribou 12% to $11.2M) and select financials (South Plains 13.6% NII growth), offset by pervasive margin compression (TriSalus GM -150bps to 84.6%, Ciena -20bps to 43.8%) and widening net losses (TriSalus -30.6% to $39.2M, Caribou flat at $148M amid impairments). Mixed sentiment dominates (14/20 detailed), driven by top-line beats/guidance reaffirms (TriSalus exceeded FY25, reaffirms 2026 $60-62M) but elevated costs/op-ex (S&M/G&A up double-digits across biotech) and litigation costs (Moderna $950M settlement). Capital allocation favors buybacks (Ciena $80.5M, News Corp $1B program) and dividends (NewLake Q1 2026 $0.43/share), with healthcare firms pursuing M&A/raises (TriSalus $46M offering, Moderna royalty-free license). Portfolio-level trends show 7/12 revenue reporters >20% YoY growth but 6/8 with op loss expansion; proxy season ramps with 8 Apr 2026 meetings signaling comp votes amid strong TSR (BNY 178%, First Business 235%). Critical developments: litigation resolutions (Moderna) and board enhancements (PacBio AI expert) provide catalysts, implying selective healthcare upside amid financial stability.

17 high priority 14 medium 31 total filings
· daily

Global High-Priority Regulatory Events — March 05, 2026

Across 285 filings from March 5, 2026, key themes include a surge in SPAC IPOs and mergers (e.g., Pasqal at $2B valuation, QuasarEdge, KPET), quantum computing catalysts (Pasqal, Xanadu), and distress in infrastructure/energy (multiple Jaiprakash defaults at ₹55k Cr debt, Cumulus Chapter 11, SKIL insolvency). Period-over-period trends show mixed revenue growth (avg +12% YoY in airlines/tech like LATAM +11%, CrowdStrike +22%; declines in media/energy like StubHub -1.4%, Stabilis -6.9%), margin compression in 15/50 quantified cos (avg -100bps, e.g., Full House EBITDA flat), and capex/debt rises amid M&A. Biotech/pharma mixed (Tenaya-Alnylam collab $1.13B milestones positive; Immatics loss swing), with positive leadership changes (SentinelOne CFO, Delta exec shuffles). Insider conviction low (no buys noted, sales rare), capital returns via buybacks (EPAM $300M ASR, Sysco reaffirmed). Portfolio-level: 40% mixed sentiment, quantum/SPAC bullish outliers, Indian insolvencies drag EM. Actionable: Monitor Q2-Q3 deal closes, CoC meetings.

285 high priority 285 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 05, 2026

The IPO pipeline shows robust activity on March 5, 2026, with two Cayman-based SPAC S-1 filings (QuasarEdge/QRED for $100M and KPET for $200M), a microcap charter fishing IPO (Arvana/AVNI), and Visa's S-4 exchange offer, highlighting a mix of blank-check vehicles and follow-on structures amid mixed/neutral sentiments. Period-over-period trends are sparse but reveal AVNI's FY2024 revenue flat at -0.5% YoY ($67,964 vs $68,276) yet net loss slashed 66% to $447k via 23.1% op ex cuts, contrasting SPACs' pre-revenue status with high dilution (QRED up to $8.19/share). Critical developments include QRED's PRC regulatory risks and Visa's uncapped litigation makewhole agreements, implying caution for public shareholders. Portfolio-level patterns indicate SPAC resurgence with larger average raises ($150M) but elevated redemption/dilution scenarios, while AVNI flags small-cap operational recovery post-hurricanes/repairs. Market implications favor monitoring de-SPAC catalysts over immediate IPO pops given mixed materiality (avg 9.5/10) and no historical performance data.

4 high priority 4 total filings
· daily

US Earnings Financial Results SEC Filings — March 05, 2026

Across 109 US SEC filings for Q4 FY2025/early FY2026 financial results, overarching themes include mixed revenue performance with ~55% of companies (60/109) reporting YoY growth averaging +25% (outliers like Liquidia +1031%, Hippo +26%), offset by declines in ~30% averaging -10% (e.g., Olaplex flat, Rayonier -10%), driven by sector-specific pressures in industrials/energy and boosts in biotech/fintech from collaborations/new products. Profitability improved in 65% with average net loss narrowing ~35% YoY via cost controls/impairment reversals, though 25% swung to losses amid impairments (StubHub $1.91B loss). Margin trends show compression averaging -80bps in tech/manufacturing (7/12 firms, e.g., CPI Card -430bps), expansion +150bps in financials (NIM +25bps avg across 12 banks). Capital allocation favors dividends/buybacks in 18 firms (e.g., Toro repurchases), with debt surges in 20% post-refinancing (Ferrellgas +78%). Biotech/pharma (35 filings) dominate with collab revenue +48% avg but high R&D burns; positive sentiment in 5% (Okta, CorMedix). Portfolio implication: Bullish on profitable growers (TaskUs +123% NI), cautious on high-burn biotechs; alpha in NIM-expanders amid rate cuts.

109 high priority 109 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 05, 2026

Across 12 DEF 14A proxy statements filed around March 5, 2026, a dominant theme is seeking advisory approval on 2025 executive compensation packages, director elections, and auditor ratifications ahead of clustered April 2026 annual meetings, with virtual formats in 11/12 cases. Financial firms like BNY Mellon (178% TSR outperforming S&P Financials 2.5x, 18% annualized EPS growth 2022-2025), First Business Financial (235% 5yr TSR vs peer median 66%, 11% YoY deposit growth), and Publix (superior results with peer-low comp) highlight strong period-over-period performance justifying pay, contrasting neutral filings lacking metrics. Capital allocation shines in PPG Industries ($1.9B op cash flow, $790M buybacks or 3% shares, 54th consecutive dividend hike) amid flat 2% organic sales. Portfolio-level trends show 4/12 with bullish metrics (revenue/EPS/TSR outperformance), mixed in industrials, neutral elsewhere; high prior say-on-pay support (e.g., BNY 95%) signals low dissent risk. Market implications include potential stock boosts post high-vote approvals, governance enhancements via new directors (Publix +1 to 9), and watch for SPAC merger risks in Relativity. Overall, financial sector conviction high, supporting overweight amid 2026 catalysts.

12 high priority 12 total filings
· daily

US Executive Officer Management Changes SEC — March 05, 2026

Across 34 SEC filings on US executive and director changes dated March 5, 2026, a dominant theme is proactive board refreshes and strategic leadership appointments, with 18 positive sentiment filings highlighting expertise in AI, growth, M&A, and operations, signaling confidence in scaling amid competitive markets. CFO/CAO transitions are prevalent (9 cases), including retirements (Cardinal Health, McKesson), departures to peers (Sysco's Cheung to McKesson), and promotions (GEO, Trulieve), with no major operational disruptions noted but smooth handovers emphasized. Where enriched data provides period trends, standout growth includes PACS Group's 2025 revenue +29.3% YoY to $5.29B and Sysco's FY2025 sales >$81B, alongside reaffirmed FY2026 guidance at high-end EPS $4.50-$4.60 despite CFO exit. Neutral sentiment dominates (16 filings) on routine changes, with few bearish signals like terminations without cause (Trulieve CAO) or role eliminations (Match COO). Portfolio-level patterns show healthcare/distribution sectors leading in C-suite stability via internal promotions, while tech/biotech adds AI/defense talent for innovation catalysts. Capital allocation leans toward retention via equity grants/RSUs (e.g., Invitation Homes $11.3M CEO LTIP, SentinelOne $18M CFO equity), with no dividend/buyback shifts but increased incentives tied to EBITDA/TSR. Implications favor long-term holders in refreshing boards, watch CFO handovers for earnings volatility.

34 high priority 34 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 05, 2026

In the USA Corporate Distress & Bankruptcy intelligence stream covering 51 filings from March 5, 2026, distress signals are limited with only two active Chapter 11 cases (Cumulus Media prepackaged plan with 72% support, TPI Composites asset sales amid DIP default), overshadowed by 20+ positive financings/refinancings (e.g., Pulmonx $60M term loan, Sunrise Realty $165M rev fac expansion) and debt tenders (Sirius XM $499M repurchased, Matador $420M). Period-over-period trends show mixed revenue performance: growth in OptimizeRx (+19% FY2025 YoY), Full House (+3.4% Q4 2025 YoY), but declines in GoPro (-19% FY2025 YoY) and implied sector weakness (Cumulus declining broadcast). Reverse stock splits in 5 small caps (Reviva 1:20, Aditxt/Sky Quarry 1:8, Salarius 1:12) flag microcap distress, while capital allocation leans bullish with buybacks (EPAM $300M ASR, OptimizeRx $10M program) and divestitures (Six Flags $331M for debt paydown, Community Health $112M). Forward-looking catalysts cluster in Q2 2026 (deal closings, approvals), suggesting deleveraging and liquidity boosts could stabilize portfolios. Portfolio implication: overweight structured distress resolutions and financing winners, underweight reverse-split microcaps amid Nasdaq deficiencies (Fly-E).

51 high priority 51 total filings
· daily

US SEC Trading Suspension Halt Orders — March 05, 2026

Across the single filing in the USA Trading Suspensions stream, Fly-E Group, Inc. (FLYE) faces significant regulatory headwinds with a Nasdaq deficiency notice for untimely 10-Q filing for the period ended December 31, 2025, and an ongoing SEC investigation initiated January 21, 2026. No period-over-period financial trends are detailed in the enriched data, but the late filing signals potential operational or reporting delays QoQ into Q4 2025. Sentiment is uniformly negative with high materiality (9/10), highlighting risks of delisting if compliance is not achieved by April 28, 2026, or extended to August 24, 2026. No immediate impact on trading or listing status provides short-term stability, but the dual regulatory pressures underscore vulnerability for emerging growth companies on Nasdaq. Key implications include heightened short-term volatility and potential suspension if unresolved, with no bullish portfolio-level patterns evident in this isolated case.

1 high priority 1 total filings